Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940445 · ClinicalTrials.gov registry record · NA
Impact of Synergistic Sequential Treatment (SST)
A NA study, sponsored by Lumenis Be.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT01940445 is a NA study that has completed, run by Lumenis Be. The registered enrollment target is 17 participants.
The verdict
NCT01940445, a NA study, has completed, sponsored by Lumenis Be.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
At least thirty (30) subjects, Fitzpatrick-Goldman Skin Type II-V will be enrolled in 2 clinical sites; each clinic will enroll at least 15 subjects. Subjects should present visible wrinkles and/or elastosis requiring treatment. Hypothesis: The SST will improve the appearance of the wrinkles/elastosis as well as general skin tone by at least 25% as compared to M22 ResurFX 1565nm module alone, for at least 75% of the subjects.
Interventions
- DEVICE M22 ResurFX
- DEVICE M22 ResurFX and QS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01940445
The ClinicalTrials.gov registry entry for NCT01940445 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumenis Be, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which M22 ResurFX is the first listed.
NCT01940445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01940445 about?
NCT01940445 is a clinical study titled "Impact of Synergistic Sequential Treatment (SST)". At least thirty (30) subjects, Fitzpatrick-Goldman Skin Type II-V will be enrolled in 2 clinical sites; each clinic will enroll at least 15 subjects. Subjects should present visible wrinkles and/or elastosis requiring treatment. Hypothesis: The SST will improve the appearance of the wrinkles/elast...
What is the current status of trial NCT01940445?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2013-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01940445?
The interventions under investigation include: M22 ResurFX (DEVICE), M22 ResurFX and QS (DEVICE).
Who is sponsoring clinical trial NCT01940445?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.